抗血栓涂层自膨胀支架(pEGASUS-HPC)治疗急性卒中颅内动脉夹层的多中心研究
这项七中心回顾性队列研究纳入36例症状性颅内动脉夹层所致急性缺血性卒中患者,采用pEGASUS-HPC抗血栓涂层自膨胀支架治疗。结果显示支架完全打开率94.4%,靶血管再灌注成功率100%,出院时平均mRS 2.1,随访81.8%患者功能预后良好(mRS 0-2),提示该支架技术可行且并发症负担低。
要点
- pEGASUS-HPC支架完全打开率94.4%,靶血管再灌注成功率100%,技术成功率高。
- 围术期无术中并发症,术后住院期间不良事件11.1%,其中仅2例有临床意义。
- 早期随访支架内狭窄≥50%者占14.8%,中期降至4.2%,无支架闭塞或卒中复发。
核心结论
- pEGASUS-HPC支架治疗颅内动脉夹层相关急性缺血性卒中技术可行,再灌注率高且总体并发症负担低,支持开展标准化抗血小板方案的前瞻性研究。
研究设计与样本
- 多中心回顾性队列研究,覆盖七个卒中中心,连续纳入36例因症状性颅内动脉夹层导致闭塞或严重限流性狭窄的急性缺血性卒中患者,均接受pEGASUS-HPC支架治疗。
- 主要结局包括技术成功(支架打开)和血管造影成功(靶血管再灌注时mTICI≥2b)、围术期并发症、mRS评分及随访支架通畅性。
关键影像表现/征象
- 91.7%的夹层为自发性,80.6%为闭塞性;26/29例闭塞性病例在支架置入前接受了机械取栓。
- 支架完全打开率94.4%,靶血管再灌注成功率100%。
- 平均NIHSS评分从入院11.8改善至出院4.9,出院平均mRS 2.1。
- 早期随访(平均94天)支架内狭窄≥50%发生率为14.8%,中期随访降至4.2%,无支架闭塞或复发性卒中。
诊断标准与关键数值
- 技术成功定义为支架打开,血管造影成功定义为靶血管再灌注时mTICI评分≥2b。
- 功能预后良好定义为mRS评分0-2分,随访中81.8%(27/33)患者达到。
临床应用与阅片要点
- 对于急性卒中由颅内动脉夹层所致闭塞或严重狭窄,pEGASUS-HPC支架可作为血运重建选项,尤其需兼顾抗血栓治疗时。
- 多数患者(75.0%)接受围术期静脉抗血小板桥接,77.8%出院时服用双联抗血小板治疗,提示需关注围术期抗栓管理。
- 随访中需监测支架内狭窄,早期随访狭窄≥50%发生率为14.8%,但中期降至4.2%且无闭塞。
局限性
- 回顾性研究设计,样本量较小(36例),随访影像完整率有限(早期75.0%,长期41.7%),抗血小板方案未标准化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Intracranial artery dissection (IADS) is an uncommon cause of acute ischemic stroke (AIS). In hyperacute settings, stenting is constrained by the need for intensive antiplatelet therapy. This study evaluated the antithrombogenic hydrophilic polymer-coated pEGASUS-HPC self-expanding stent for IADS-related AIS.
METHODS: This multicenter retrospective cohort study across seven stroke centers included consecutive patients with AIS and occlusion or severe flow-limiting stenosis caused by symptomatic IADS, who were treated with the pEGASUS-HPC. The outcomes were technical and angiographic success (device opening; mTICI score ≥2b when reperfusion was targeted), peri-procedural complications, mRS score, and follow-up patency.
RESULTS: In 36 treated patients (mean age 62.0 ± 19.6 years; 63.9% men), 91.7% of the dissections were spontaneous, and 80.6% were occlusive. Mechanical thrombectomy preceded stenting in 26/29 occlusive cases. Full stent opening occurred in 94.4%, and 100% reperfusion success was achieved in targeted vessels. Most patients received periprocedural intravenous antiplatelet bridging (75.0%) and were discharged on DAPT (77.8%). Whereas no intraprocedural complications occurred, four postprocedural events occurred during admission (11.1%), of which two were clinically significant and two were minor and asymptomatic. The mean NIHSS score improved from 11.8 at admission to 4.9 at discharge, and the mean discharge mRS score was 2.1. Clinical follow-up (mRS) was available in 33/36 patients (91.7%), with favorable functional outcome (mRS 0-2) in 27/33 (81.8%). Imaging follow-up at the early window (mean 94 days) was available in 27/36 (75.0%). In-stent stenosis ≥ 50% occurred in 14.8% and 4.2% of patients at early and mid-term follow-up, respectively, whereas no device occlusions or recurrent strokes occurred through mid-term follow-up. Long-term imaging follow-up (15/36, 41.7%) showed no new in-stent stenosis.
CONCLUSIONS: pEGASUS-HPC stenting for IADS-related AIS was technically feasible and achieved high reperfusion rates and a low overall complication burden, thus supporting prospective evaluation with standardized antiplatelet protocols.
引用
- Aburub A, Henkes H, Kemmling A, et al. Antithrombogenic coated self-expanding stent (pEGASUS-HPC) for the treatment of intracranial dissections of the cerebral arteries in acute stroke: a multicenter study. Neuroradiology. 2026. PMID: 42530625. doi:10.1007/s00234-026-04119-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。